K
KymaThera develops precision therapeutics by targeting well-characterized, dysregulated disease drivers for areas of high unmet medical need. The company's pipeline includes a highly selective PI3K$\alpha$ inhibitor for oncology and a potent inhaled ALK5 inhibitor for pulmonary fibrosis. These programs aim to deliver improved efficacy and safety profiles over existing treatments through structure-based drug design.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- This platform appears to host a "Robot Challenge Screen," suggesting a focus on competitive robotics or simulation environments. The site requires user interaction, likely involving enabling cookies for functionality. The core service seems centered around a digital interface for robotics challenges or testing.